10x Genomics Inc Class A (TXG)

In Q2 2025, 10x Genomics reported earnings per share of $0.28 and revenue of $172.91 million, surpassing analyst estimates, but the stock fell 2.92% post-earnings. The company launched Xenium Protein, advancing spatial biology. Several insiders sold shares of company stock. Analyst ratings varied, with some firms adjusting price targets and ratings. 10x Genomics announced a partnership with Anthropic to integrate its analysis tools into Claude for Life Sciences, causing the stock to rise 8%. The company entered into an agreement to acquire Scale Biosciences, Inc.

Historical data suggests that for 10x Genomics, Inc., there can be seasonal patterns in its stock performance, with October historically leaning short. The company's revenue is primarily generated from the sale of instruments and recurring consumables. Continuous innovation and expansion of product offerings, along with global partnerships, are aimed at supporting resilient, long-term revenue streams.

10x Genomics, Inc. is a life science technology company that develops and sells integrated solutions for analyzing biological systems. Its major product platforms include the Chromium Platform for high-throughput analysis, the Visium Platform for spatial gene expression analysis, and the Xenium Platform for in situ analysis. The company generates revenue from selling instruments and consumables, serving academic, government, biopharmaceutical, and biotechnology institutions.

10x Genomics, Inc. has a global geographic footprint, developing and selling its products in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. Its headquarters are located in Pleasanton, California, USA.

10x Genomics has maintained a reputation as a significant force in biological research, providing groundbreaking single-cell, spatial, and in situ analysis instruments and consumables. The company's partnership with Anthropic, the launch of Xenium Protein, and the partnership with CLISEQ Ltd. and Weizmann Institute have positively impacted its reputation. Analyst consensus currently rates the stock as "Hold."

Approximately 46.79% of 10x Genomics' stock is owned by institutional investors, 2.31% by insiders, and 50.90% by public companies and individual investors. Major institutional owners include ARK Investment Management LLC, Vanguard Group Inc, and BlackRock, Inc. Cathie Wood owns the most shares among individual investors.